E
Y-mAbs Therapeutics, Inc. YMAB
$11.60 -$0.25-2.11%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
E
Sell 1/9/2024Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 1/9/2024 due to a decline in the valuation index.
D
Sell 6/23/2023Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E+ on 6/23/2023 due to an increase in the total return index, growth index and volatility index.
E
Sell 3/14/2023Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
D
Sell 2/23/2023Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
E
Sell 2/8/2023Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell 11/23/2022Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 11/23/2022 due to a decline in the total return index and volatility index.
D
Sell 11/3/2022Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 11/3/2022 due to an increase in the valuation index.
D
Sell 9/19/2022Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 9/19/2022 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.6422 to -$0.9408, EBIT declined 44.23% from -$27.7M to -$39.95M, and the quick ratio declined from 5.72 to 4.78.
D
Sell 6/21/2022Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 6/21/2022 due to an increase in the volatility index and total return index.
D
Sell 6/3/2022Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 6/3/2022 due to a decline in the volatility index and valuation index.
D
Sell 5/16/2022Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell 5/13/2022Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 5/13/2022 due to a noticeable decline in the solvency index. The quick ratio declined from 6.79 to 5.72.
D
Sell 5/5/2022Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
E
Sell 4/20/2022Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 8.79 to 6.79.
D
Sell 2/23/2022Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 2/23/2022 due to a noticeable decline in the total return index and volatility index.
D
Sell 11/23/2021Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell 11/8/2021Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 11/8/2021 due to a decline in the efficiency index, volatility index and valuation index. Net income declined 25.81% from -$22.94M to -$28.86M, and total capital declined 10.1% from $237.32M to $213.35M.
D
Sell 3/16/2020Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 3/16/2020 due to an increase in the solvency index, efficiency index and growth index. Total capital increased 127.85% from $88.28M to $201.13M, the quick ratio increased from 7.02 to 15.25, and debt to equity declined from 0.01 to 0.
D
Sell 3/11/2020Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 3/11/2020 due to a decline in the volatility index.
D
Sell 12/6/2019Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 12/6/2019 due to a noticeable increase in the total return index and volatility index.
D
Sell 6/3/2019Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E on 6/3/2019 due to an increase in the volatility index, efficiency index and total return index.
E
Sell 3/4/2019Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to E from E- on 3/4/2019 due to an increase in the total return index and valuation index.
E
Sell 12/17/2018None
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E- from U on 12/17/2018.
Weiss Ratings